Clinical trial
BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer
NCT00049244 · R-Pharm, Industry · Unknown status
Key facts
| NCT number | NCT00049244 |
|---|---|
| Title | BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer |
| Official title | A Phase I Study of BMS-247550 in Combination With Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With a Taxane and an Anthracycline |
| Lead sponsor | R-Pharm, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, ixabepilone |
| Start date | Sep 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 30, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: